Metronomic Chemotherapy (mCHT) in HER2-ve Advanced Breast Cancer (ABC) Patients (PTS): When Care Objectives Meet Patients’ Need. Preliminary Results of the Victor-6 Study
Marina Elena Cazzaniga(Azienda Ospedaliera San Gerardo), Valter Torri(Istituti di Ricovero e Cura a Carattere Scientifico), Maria Rosaria Valerio(Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo), Rosalba Rossello(Fondazione Vincenzo Pansadoro), Vittorio Gebbia(Università degli Studi di Enna Kore), Silvana Saracchini(Centro di Riferimento Oncologico), Erico Maria Romani Deconciliis, Lucia Stocchi(Ospedale Infermi di Rimini), Anna Maria Vandone(Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo), Maria Concetta Cursano(Università Campus Bio-Medico), Luigi Cavanna(University of Pavia), Salvatorico Ortu, Giovanni Scognamiglio(Ospedale Valduce), Salvatore Russo(Imperial College Healthcare NHS Trust), Virginia Casadei(San Salvatore Hospital), Stefania Pedroli, D. Toniolo(CTO Hospital), Elisabetta Melegari(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Graziella Pinotti(Medica (Italy)), Benedetta Pellegrino(University of Parma)
Cited by 0
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
|The Lancet Oncology|2015|1.1k
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
|The Lancet Oncology|2016|1k
Chemotherapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III Randomized Trial
|JNCI Journal of the National Cancer Institute|2003|795
Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
|New England Journal of Medicine|2014|751